Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radioprotectants: current status and new directions.

David J Grdina1, Jeffrey S Murley, Yasushi Kataoka

  • 1Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Ill. 60637, USA. dgrdina@rover.uchicago.edu

Oncology
|December 6, 2002
PubMed
Summary

Amifostine protects against radiation toxicity, like xerostomia, without reducing cancer treatment effectiveness. Research explores amifostine and other methods to improve cancer therapy safety and reduce side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proof of principle study: synchrotron X-ray fluorescence microscopy for identification of previously radioactive microparticles and elemental mapping of FFPE tissues.

Scientific reports·2023
Same author

Epidemiological Study of Pathogenic <i>Leptospira</i> in Raccoons (<i>Procyon lotor</i>) in a Suburb of Tokyo, Japan.

Animals : an open access journal from MDPI·2023
Same author

PERIOD 2 regulates low-dose radioprotection via PER2/pGSK3β/β-catenin/Per2 loop.

iScience·2022
Same author

Efficacy of antimicrobial therapy for bovine acute Klebsiella pneumoniae mastitis.

The Journal of veterinary medical science·2022
Same author

Severe fishhook-related ocular injury: A case series.

Trauma case reports·2021
Same author

Fecal microbiota transplantation as a new treatment for canine inflammatory bowel disease.

Bioscience of microbiota, food and health·2021

Area of Science:

  • Oncology
  • Radiotherapy
  • Pharmacology

Background:

  • Radiotherapy can cause significant normal tissue toxicity, impacting cancer patient outcomes.
  • Amifostine is a cytoprotective agent clinically proven to reduce radiation-induced toxicity, notably xerostomia in head and neck cancer patients.
  • The active metabolite of amifostine (WR-1065) demonstrates in vitro potential in preventing radiation-induced cell death and mutagenesis.

Purpose of the Study:

  • To review current and novel cytoprotective therapies for radiotherapy.
  • To highlight amifostine's role in mitigating radiation-induced toxicities.
  • To discuss emerging strategies for enhancing the therapeutic ratio in cancer treatment.

Main Methods:

  • Review of amifostine's clinical and in vitro efficacy in preventing radiotherapy side effects.

Related Experiment Videos

  • Exploration of novel radioprotective approaches, including manganese superoxide dismutase (MnSOD) enhancement.
  • Investigation into epoetin alfa for treating radiation-induced anemia, alone or with cytoprotectants.

    • Main Results:

    • Amifostine effectively reduces radiation-induced xerostomia and shows potential in preventing mutagenesis.
    • Ongoing research focuses on amifostine's ability to prevent secondary tumors and other radiation toxicities.
    • Epoetin alfa is being investigated for managing radiation-induced anemia.

    Conclusions:

    • Cytoprotective therapies like amifostine are crucial for improving cancer patient quality of life.
    • Developing novel radioprotective strategies is essential for enabling more intensive and effective anticancer treatments.
    • The ultimate goal is to enhance the therapeutic ratio by minimizing acute and chronic toxicities.